268 related articles for article (PubMed ID: 35488944)
1. The Time to Reconsider Mineralocorticoid Receptor Blocking Strategy: Arrival of Nonsteroidal Mineralocorticoid Receptor Blockers.
Tezuka Y; Ito S
Curr Hypertens Rep; 2022 Jul; 24(7):215-224. PubMed ID: 35488944
[TBL] [Abstract][Full Text] [Related]
2. Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists.
Sueta D; Yamamoto E; Tsujita K
Curr Hypertens Rep; 2020 Feb; 22(3):21. PubMed ID: 32114686
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
Lerma E; White WB; Bakris G
Postgrad Med; 2023 Apr; 135(3):224-233. PubMed ID: 35392754
[TBL] [Abstract][Full Text] [Related]
4. Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease.
Wan N; Rahman A; Nishiyama A
J Hum Hypertens; 2021 Feb; 35(2):148-156. PubMed ID: 32661269
[TBL] [Abstract][Full Text] [Related]
5. Effects of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, on Cardiovascular Disease, Chronic Kidney Disease, and Blood Pressure.
Ravid JD; Laffin LJ
Curr Cardiol Rep; 2022 Oct; 24(10):1251-1259. PubMed ID: 35925515
[TBL] [Abstract][Full Text] [Related]
6. Role of mineralocorticoid receptor antagonists in kidney diseases.
Patel V; Joharapurkar A; Jain M
Drug Dev Res; 2021 May; 82(3):341-363. PubMed ID: 33179798
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic perspective: evolving evidence of nonsteroidal mineralocorticoid receptor antagonists in diabetic kidney disease.
Yao L; Liang X; Wang P
Am J Physiol Endocrinol Metab; 2023 Jun; 324(6):E531-E541. PubMed ID: 37166263
[TBL] [Abstract][Full Text] [Related]
8. [Research progress on the cardiorenal protection of non-steroid mineralocorticoid receptor antagonists in patients with chronic kidney disease].
Liu WY; Yu SQ
Sheng Li Xue Bao; 2022 Dec; 74(6):1023-1030. PubMed ID: 36594390
[TBL] [Abstract][Full Text] [Related]
9. Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.
Pandey AK; Bhatt DL; Cosentino F; Marx N; Rotstein O; Pitt B; Pandey A; Butler J; Verma S
Eur Heart J; 2022 Aug; 43(31):2931-2945. PubMed ID: 35713973
[TBL] [Abstract][Full Text] [Related]
10. Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - New perspectives for combination therapy.
Kolkhof P; Joseph A; Kintscher U
Pharmacol Res; 2021 Oct; 172():105859. PubMed ID: 34461222
[TBL] [Abstract][Full Text] [Related]
11. Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone-Translational Aspects and Clinical Perspectives across Multiple Organ Systems.
Kolkhof P; Lawatscheck R; Filippatos G; Bakris GL
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012508
[TBL] [Abstract][Full Text] [Related]
12. New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure.
Capelli I; Gasperoni L; Ruggeri M; Donati G; Baraldi O; Sorrenti G; Caletti MT; Aiello V; Cianciolo G; La Manna G
J Nephrol; 2020 Feb; 33(1):37-48. PubMed ID: 30989614
[TBL] [Abstract][Full Text] [Related]
13. Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats.
Li L; Guan Y; Kobori H; Morishita A; Kobara H; Masaki T; Nakano D; Nishiyama A
Hypertens Res; 2019 Jun; 42(6):769-778. PubMed ID: 30587856
[TBL] [Abstract][Full Text] [Related]
14. Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone.
Rakugi H; Yamakawa S; Sugimoto K
Hypertens Res; 2021 Apr; 44(4):371-385. PubMed ID: 33214722
[TBL] [Abstract][Full Text] [Related]
15. The Role of the Mineralocorticoid Receptor and Mineralocorticoid Receptor-Directed Therapies in Heart Failure.
Young MJ; Kanki M; Karthigan N; Konstandopoulos P
Endocrinology; 2021 Nov; 162(11):. PubMed ID: 34050730
[TBL] [Abstract][Full Text] [Related]
16. Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blocker.
Arai K; Morikawa Y; Ubukata N; Sugimoto K
Hypertens Res; 2020 Nov; 43(11):1204-1213. PubMed ID: 32616846
[TBL] [Abstract][Full Text] [Related]
17. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review.
Bomback AS; Kshirsagar AV; Amamoo MA; Klemmer PJ
Am J Kidney Dis; 2008 Feb; 51(2):199-211. PubMed ID: 18215698
[TBL] [Abstract][Full Text] [Related]
18. Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice.
Bhuiyan AS; Rafiq K; Kobara H; Masaki T; Nakano D; Nishiyama A
Hypertens Res; 2019 Jun; 42(6):892-902. PubMed ID: 30664703
[TBL] [Abstract][Full Text] [Related]
19. Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease.
Bramlage P; Swift SL; Thoenes M; Minguet J; Ferrero C; Schmieder RE
Eur J Heart Fail; 2016 Jan; 18(1):28-37. PubMed ID: 26634965
[TBL] [Abstract][Full Text] [Related]
20. Crystal structure of the mineralocorticoid receptor ligand-binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS-3150).
Takahashi M; Ubukata O; Homma T; Asoh Y; Honzumi M; Hayashi N; Saito K; Tsuruoka H; Aoki K; Hanzawa H
FEBS Lett; 2020 May; 594(10):1615-1623. PubMed ID: 31991486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]